BioLineRx
BioLineRx

BioLineRx

Biotechnology
WebsiteInvestor RelationsSEC
BioLine Rx Ltd is a commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has a legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.

$11M

Market Cap • 10/9/2026

2003

(23 years)

Founded

2011

(15 years ago)

IPO

NASDAQ

Listing Exchange

Flag of Israel

Israel

Country

Valuation

P/B

0,8

P/S

7,9

P/EBITDA

—

P/OCF

—

P/FCF

—

P/E

—

BVPS

2,8

EPS

—

Market Cap

Market Cap

11M

EV

8,7M

EV/Revenue

6,3

EV/EBITDA

-0,7

EV/EBIT

-0,7

Payout

Dividend Per Share

0

Dividend Yield

0%

Buyback Yield

-3,5%

Total Yield

-3,5%

Payout

0%

Retained Earnings

-405,6M

Profitability

Gross Margin

80%

EBITDA Margin

—

EBIT Margin

—

Net Margin

—

D&A/EBITDA

0%

R&D/Revenue

690,7%

Capex/Revenue

0%

Capex/D&A

0%

Capex/OCF

0%

SBC/OCF

—

% PPE

2,4%

% Goodwill

0%

ROE

—

ROIC

—

Growth

CAGR Op. Income 5Y

-11,6%

CAGR Net Income 5Y

-21,3%

CAGR EPS 5Y

-100%

CAGR OCF 5Y

-14,7%

Leverage

N.D./EBITDA

0,4

Debt/Equity

0%

Current Ratio

1,2

Quick Ratio

1

Interest Coverage

—

Premium

Unlock 100% of the data and have immediate access on more than 6.000 companies with updated information!
  • Unrestricted access
  • Unlimited data history
  • Analysis videos
  • Quarterly highlights
  • Customizable financials table
  • Ranking
  • Discussions

...and much more!

Get Premium